Posted by Michael Wonder on 18 Dec 2024
Jemperli (dostarlimab) receives US FDA breakthrough therapy designation for locally advanced dMMR/MSI-H rectal cancer
16 December 2024 - Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab.
GSK announced today that the US FDA has granted breakthrough therapy designation for Jemperli (dostarlimab) for the treatment of patients with locally advanced mismatch repair deficient/microsatellite instability-high rectal cancer.
